278 related articles for article (PubMed ID: 23831532)
1. Evaluation of neuropeptide loaded trimethyl chitosan nanoparticles for nose to brain delivery.
Kumar M; Pandey RS; Patra KC; Jain SK; Soni ML; Dangi JS; Madan J
Int J Biol Macromol; 2013 Oct; 61():189-95. PubMed ID: 23831532
[TBL] [Abstract][Full Text] [Related]
2. Preparation and evaluation of anti-neuroexcitation peptide (ANEP) loaded N-trimethyl chitosan chloride nanoparticles for brain-targeting.
Wang S; Jiang T; Ma M; Hu Y; Zhang J
Int J Pharm; 2010 Feb; 386(1-2):249-55. PubMed ID: 19900520
[TBL] [Abstract][Full Text] [Related]
3. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system.
Amidi M; Romeijn SG; Borchard G; Junginger HE; Hennink WE; Jiskoot W
J Control Release; 2006 Mar; 111(1-2):107-16. PubMed ID: 16380189
[TBL] [Abstract][Full Text] [Related]
4. TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines.
Sayin B; Somavarapu S; Li XW; Sesardic D; Senel S; Alpar OH
Eur J Pharm Sci; 2009 Nov; 38(4):362-9. PubMed ID: 19733658
[TBL] [Abstract][Full Text] [Related]
5. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery.
Yin L; Ding J; He C; Cui L; Tang C; Yin C
Biomaterials; 2009 Oct; 30(29):5691-700. PubMed ID: 19615735
[TBL] [Abstract][Full Text] [Related]
6. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
Slütter B; Bal S; Keijzer C; Mallants R; Hagenaars N; Que I; Kaijzel E; van Eden W; Augustijns P; Löwik C; Bouwstra J; Broere F; Jiskoot W
Vaccine; 2010 Aug; 28(38):6282-91. PubMed ID: 20638455
[TBL] [Abstract][Full Text] [Related]
7. Lipophilic derivatives of leu-enkephalinamide: in vitro permeability, stability and in vivo nasal delivery.
Cros CD; Toth I; Blanchfield JT
Bioorg Med Chem; 2011 Feb; 19(4):1528-34. PubMed ID: 21273080
[TBL] [Abstract][Full Text] [Related]
8. Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation.
Paliwal R; Paliwal SR; Agrawal GP; Vyas SP
Int J Pharm; 2012 Jan; 422(1-2):179-84. PubMed ID: 22079712
[TBL] [Abstract][Full Text] [Related]
9. Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization.
Shahnaz G; Vetter A; Barthelmes J; Rahmat D; Laffleur F; Iqbal J; Perera G; Schlocker W; Dünnhaput S; Augustijns P; Bernkop-Schnürch A
Int J Pharm; 2012 May; 428(1-2):164-70. PubMed ID: 22421322
[TBL] [Abstract][Full Text] [Related]
10. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease.
Meng Q; Wang A; Hua H; Jiang Y; Wang Y; Mu H; Wu Z; Sun K
Int J Nanomedicine; 2018; 13():705-718. PubMed ID: 29440896
[TBL] [Abstract][Full Text] [Related]
11. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination.
Verheul RJ; Slütter B; Bal SM; Bouwstra JA; Jiskoot W; Hennink WE
J Control Release; 2011 Nov; 156(1):46-52. PubMed ID: 21784113
[TBL] [Abstract][Full Text] [Related]
12. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
Fazil M; Md S; Haque S; Kumar M; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2012 Aug; 47(1):6-15. PubMed ID: 22561106
[TBL] [Abstract][Full Text] [Related]
13. Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain.
Hanafy AS; Farid RM; ElGamal SS
Drug Dev Ind Pharm; 2015; 41(12):2055-68. PubMed ID: 26133084
[TBL] [Abstract][Full Text] [Related]
14. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
[TBL] [Abstract][Full Text] [Related]
15. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
Amidi M; Romeijn SG; Verhoef JC; Junginger HE; Bungener L; Huckriede A; Crommelin DJ; Jiskoot W
Vaccine; 2007 Jan; 25(1):144-53. PubMed ID: 16973248
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of folate conjugated N-trimethyl chitosan nanoparticles as protein carrier targeting folate receptor: in vitro studies.
Zheng Y; Cai Z; Song X; Chen Q; Bi Y; Li Y; Hou S
J Drug Target; 2009 May; 17(4):294-303. PubMed ID: 19255895
[TBL] [Abstract][Full Text] [Related]
17. "Application of Box-Behnken design for optimization and development of quetiapine fumarate loaded chitosan nanoparticles for brain delivery via intranasal route* ".
Shah B; Khunt D; Misra M; Padh H
Int J Biol Macromol; 2016 Aug; 89():206-18. PubMed ID: 27130654
[TBL] [Abstract][Full Text] [Related]
18. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain.
Wang ZH; Wang ZY; Sun CS; Wang CY; Jiang TY; Wang SL
Biomaterials; 2010 Feb; 31(5):908-15. PubMed ID: 19853292
[TBL] [Abstract][Full Text] [Related]
19. Evaluation and modification of N-trimethyl chitosan chloride nanoparticles as protein carriers.
Chen F; Zhang ZR; Huang Y
Int J Pharm; 2007 May; 336(1):166-73. PubMed ID: 17145144
[TBL] [Abstract][Full Text] [Related]
20. Brain delivery of buspirone hydrochloride chitosan nanoparticles for the treatment of general anxiety disorder.
Bari NK; Fazil M; Hassan MQ; Haider MR; Gaba B; Narang JK; Baboota S; Ali J
Int J Biol Macromol; 2015 Nov; 81():49-59. PubMed ID: 26210037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
